Lantheus Holdings, Inc. (LNTH)
NASDAQ: LNTH · Real-Time Price · USD
102.10
0.00 (0.00%)
At close: Nov 20, 2026, 4:00 PM EST
102.00
-0.10 (-0.10%)
After-hours: Nov 20, 2026, 7:49 PM EST
Lantheus Holdings Revenue
Lantheus Holdings had revenue of $389.91M in the quarter ending September 30, 2026, with 1.54% growth. This brings the company's total for the last twelve months to $1.56B, up 2.38% year-over-year. In the year 2025, Lantheus Holdings had annual revenue of $1.54B with 0.50% growth. That makes Lantheus Holdings the 5,855th largest company in the world by revenue and 1,478th in the United States.
Revenue (ttm)
$1.56B
Revenue Growth
+2.38%
P/S Ratio
4.27
Revenue / Employee
$1,309,482
Employees
1,193
Market Cap
6.68B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Lantheus Holdings breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.54B | 7.70M | 0.50% |
| Dec 31, 2024 | 1.53B | 237.48M | 18.32% |
| Dec 31, 2023 | 1.30B | 361.37M | 38.65% |
| Dec 31, 2022 | 935.06M | 509.85M | 119.91% |
| Dec 31, 2021 | 425.21M | 85.80M | 25.28% |
| Dec 31, 2020 | 339.41M | -7.93M | -2.28% |
| Dec 31, 2019 | 347.34M | 3.96M | 1.15% |
| Dec 31, 2018 | 343.37M | 12.00M | 3.62% |
| Dec 31, 2017 | 331.38M | 29.53M | 9.78% |
| Dec 31, 2016 | 301.85M | 8.39M | 2.86% |
| Dec 31, 2015 | 293.46M | -8.14M | -2.70% |
| Dec 31, 2014 | 301.60M | 17.93M | 6.32% |
| Dec 31, 2013 | 283.67M | -4.43M | -1.54% |
| Dec 31, 2012 | 288.11M | -68.19M | -19.14% |
| Dec 31, 2011 | 356.29M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 11.11B |
| Elanco Animal Health | 5.15B |
| Dr. Reddy's Laboratories | 3.44B |
| Amneal Pharmaceuticals | 3.20B |
| Hims & Hers Health | 2.87B |
| Alkermes | 1.75B |
| Supernus | 1.37B |
| Kiniksa Pharmaceuticals International, | 945.96M |
LNTH News
- 5 days ago - Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer's Disease - GlobeNewsWire
- 10 days ago - Lantheus selling its CDMO business and NJ manufacturing facility to PharmaLogic - TheFly
- 11 days ago - PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility - PRNewsWire
- 16 days ago - Lantheus reports Q3 adjusted EPS $1.68, consensus $1.26 - TheFly
- 16 days ago - Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals - GlobeNewsWire
- 16 days ago - Lantheus Reports Third Quarter 2026 Financial Results - GlobeNewsWire
- 16 days ago - Lantheus Holdings Earnings release: Q3 2026 - Filings
- 16 days ago - Lantheus Holdings Quarterly report: Q3 2026 - Filings